

# Datasheet: TZA002P BATCH NUMBER 166334

Description:	HUMAN ANTI DURVALUMAB (DRUG/TARGET COMPLEX):HRP		
Specificity:	DURVALUMAB DRUG/TARGET COMPLEX		
Other names:	Imfinzi		
Format:	HRP		
Product Type:	Monoclonal Antibody		
Clone:	AbD41240		
Isotype:	Fab antibody		
Quantity:	0.1 mg		

## **Product Details**

Applications	This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit <u>www.bio-rad-antibodies.com/protocols</u> .					
		Yes	No	Not Determined	Suggested Dilution	
	ELISA	-				
	Where this product has not been tested for use in a particular technique this does no necessarily exclude its use in such procedures. Suggested working dilutions are give a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.					
Product Form	A bivalent human recombinant Fab (lambda light chain) generated by coupling of the monovalent SpyTagged Fab <u>TZA002</u> with a HRP conjugated BiSpyCatcher version 2. The coupled antibody has two DYKDDDDK tags and three His6-tags. It contains SpyTag3 peptide ( <u>BLP086</u> ) in 5-fold molar excess to block any unreacted Catcher sites. This antibody is supplied as a liquid.					
Preparation	Metal chelate affinity chr	omatograp	hy			
Source	E.coli					
Buffer Solution	Phosphate buffered saline					
Preservative Stabilisers	0.0095% MIT					
Approx. Protein	Antibody concentration (	).5 mg/ml				

Concentrations						
Immunogen	PD-L1/Durvalumab complex					
Specificity	Human Anti-Durvalumab (Drug/Target Complex) Antibody, clone AbD41240 specifically recognizes the antibody drug durvalumab when in complex with its target, PD-L1 (programmed cell death ligand 1). The antibody does not recognize free durvalumab nor unbound recombinant human PD-L1. It can be used to measure levels of durvalumab in patient samples.					
	This TrailBlazer Antibody is available in two different formats, monovalent Fab unconjugated (TZA002) and bivalent Fab conjugated to HRP (TZA002P). The monovalent recombinant Fab antibody has a SpyTag incorporated, which is used to create the bivalent format by coupling two SpyTagged Fab antibodies to an HRP conjugated BiSpyCatcher2 (TZC002P). Either format can be used to develop a pharmacokinetic (PK) antigen capture assay to measure free durvalumab captured via immobilized PD-L1.					
	The antibody is tagged with a SpyTag2 at the C-terminus of the Fab antibody heavy chain, enabling the user to couple it to any of the SpyCatchers in our catalog for conversion to alternative formats in less than one hour.					
	View a summary of all SpyCatcher products					
	Durvalumab (Imfinzi) is a human IgG1/kappa antibody with allotype G1m3. The CH2 domain was engineered with three amino acid substitutions (L238F, L239E, P335S) to reduce the Fc-mediated effector functions to prevent depletion of PD-L1+ T-cells. It was first approved for previously treated patients with advanced bladder cancer. It was later approved for the treatment of unresectable stage 3 NSCLC (Non-Small Cell Lung Cancer) and ES-SCLC. Durvalumab binds to PD-L1 to block the interaction with the inhibitory T cell receptor PD-1. This blockade removes the suppression of T-cells that are specific for MHC-1-presented neoepitopes on tumor cells. Removal of this inhibitory signal leads to the release of granzymes and perforins by the activated T-cells, and finally to the destruction of the tumor cells.					
	View a summary of all anti-durvalumab antibodies					
Affinity	The monovalent intrinsic affinity of AbD41240pap was measured as $K_D$ = 13 nM by real time, label free molecular interaction analysis on immobilized durvalumab in complex with PD-L1.					
ELISA	Clone AbD41240pap can be used in a pharmacokinetic (PK) antigen capture ELISA to measure durvalumab captured via immobilized human PD-L1 or to measure the level of durvalumab/PD-L1 complex. Protocol: <u>PK antigen capture ELISA</u>					
Storage	This product is shipped frozen. When ready to use, thaw and aliquot the sample as needed. Store aliquots at -70°C, if available, otherwise store at -20°C. It is not recommended to keep aliquots at 4°C for					

	more than one week.
Guarantee	12 months from date of despatch
Acknowledgements	This product and/or its use is covered by claims of U.S. patents, and/or pending U.S. and non-U.S. patent applications owned by or under license to Bio-Rad Laboratories, Inc. See bio-rad.com/en-us/trademarks for details. His-tag is a registered trademark of EMD Biosciences. Imfinzi is a trademark of Medimmune/AstraZeneca using Abgenix's XenoMouse® technology
Health And Safety Information	Material Safety Datasheet documentation #20479 available at: https://www.bio-rad-antibodies.com/SDS/TZA002P 20479
Licensed Use	For <i>in vitro</i> research purposes only, unless otherwise specified in writing by Bio-Rad.
Regulatory	For research purposes only
Technical Advice	Recommended protocols for coupling a Fab antibody with a SpyTag to a SpyCatcher can be found at <u>SpyTag and SpyCatcher Products</u> , and further information about HuCAL recombinant antibody technology can be found in the <u>HuCAL Antibodies Technical Manual</u>

## Related Products

### **Recommended Useful Reagents**

SpyTag3 PEPTIDE (BLP086) HISPEC ASSAY DILUENT (BUF049A) HUMAN ANTI DURVALUMAB (DRUG/TARGET COMPLEX) (TZA002) HUMAN ANTI DURVALUMAB (HCA359) HUMAN ANTI DURVALUMAB (HCA360) HUMAN ANTI DURVALUMAB (TZA004)

North & South	Tel: +1 800 265 7376	Worldwide	Tel: +44 (0)1865 852 700	Europe	Tel: +49 (0) 89 8090 95 21
America	Fax: +1 919 878 3751		Fax: +44 (0)1865 852 739		Fax: +49 (0) 89 8090 95 50
	Email: antibody_sales_us@bio-rad.com		Email: antibody_sales_uk@bio-rad.com		Email: antibody_sales_de@bio-rad.com

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets 'M422715:230925'

#### Printed on 05 Mar 2024

© 2024 Bio-Rad Laboratories Inc | Legal | Imprint